All Content Outsourced Pharma

  1. The Systems And Choreography Needed For Grade B ATMP Material Transfer 3/31/2026

    Traditional material air locks often fail to account for the sheer throughput needed for cell therapy workflows. These design tips help prevent traffic jams.

  2. Synthetic DNA As An Alternative For Scalable Viral Vector Production 3/30/2026

    Enzymatically synthesized DNA is assessed as a plasmid alternative, showing comparable viral vector yield, quality, and purification, while improving scalability and regulatory flexibility.

  3. Phio Pharmaceuticals Announces Agreement With U.S. cGMP Manufacturing Source For Drug Product, PH-762 3/30/2026

    Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL gene silencing technology to eliminate cancer.

  4. Does Biotech Need More Government Funding — Or A New Business Model? 3/30/2026

    Should government financing appreciably recede – whether through policy shifts, budget pressures, or ideological bent – what would happen to the biotech business model? To ascertain such a question, first we must look at the fundamentals of the existing model, and then understand investors (and service providers) better.

  5. ImmuneOncia Therapeutics And Lonza Collaborate To Manufacture Danburstotug, A PD-L1 Antibody Targeting Immuno-Oncology 3/30/2026

    ImmuneOncia Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on immuno-oncology, and Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced today that the companies signed a manufacturing agreement for late-stage clinical supply of Danburstotug (IMC-001).

  6. uBriGene And Cellinfinity BIO Announce Strategic Partnership To Advance In Vivo CAR-T Therapies 3/30/2026

    uBriGene Biosciences, a leading global CDMO specializing in lentiviral vector manufacturing and Advanced Therapy Medicinal Product (ATMP) development, today announced a strategic partnership with Cellinfinity BIO, a biotechnology company developing in vivoCAR-T therapies targeting hematologic and solid tumors.

  7. Immobilized Enzymes Promise Alternative To Cyanogen Bromide's Toxicity 3/27/2026

    Proteases may be more expensive up front, but the benefits of cutting out a highly toxic substance quickly add up when disposal and environmental safety costs go down.

  8. Rethinking ATMP Assurance When Sterility Timelines, Reality Misalign 3/27/2026

    The compendial 14-day sterility testing window exposes product and patient to numerous risks, but settling on a rapid alternative also presents its own set of challenges.

  9. Investing In Early-Stage Oncology With Yosemite's Dan McHugh 3/26/2026

    On this week's episode of the Business of Biotech, Dan McHugh, head of the investment team at Yosemite, explains the San Francisco VC group's approach to investing in early-stage cancer therapeutics and funding academic research through unrestricted grants.

  10. Mammalian Cell Line Development 3/26/2026

    Explores how modern cell line engineering boosts speed, stability, and scalability across biologics, with practical insights to cut risk and improve readiness for downstream development.